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Abstract
Objective: To quantify the impact of inflammatory brain diseases in the pediatric population on health-related
quality of life, including the subdomains of physical, emotional, school and social functioning.
Methods: This was a multicenter, observational cohort study of children (< 18 years of age) diagnosed with
inflammatory brain disease (IBrainD). Patients were included if they had completed at least one Health
Related Quality of Life Questionnaire (HRQoL). HRQoL was measured using the Pediatric Quality of Life
Inventory Version 4.0 (PedsQL) Generic Core Scales, which provided a total score out of 100. Analyses of
trends were performed using linear regression models adjusted for repeated measures over time.
Results: In this study, 145 patients were included of which 80 (55%) were females. Cognitive dysfunction was
the most common presenting symptoms (63%), and small vessel childhood primary angiitis of the CNS was
the most common diagnosis (33%). The mean child’s self-reported PedsQL total score at diagnosis was 68.4,
and the mean parent’s proxy-reported PedsQL score was 63.4 at diagnosis. Child’s self-reported PedsQL scores
reflected poor HRQoL in 52.9% of patients at diagnosis. Seizures or cognitive dysfunction at presentation was
associated with statistically significant deficits in HRQoL.
Conclusion: Pediatric IBrainD is associated with significantly diminished health-related quality of life. Future
research should elucidate why these deficits occur and interventions should focus on improving HRQoL in
the most affected subdomains, in particular for children presenting with seizures and cognitive dysfunction.
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Introduction
Childhood inflammatory brain diseases (IBrainDs) encom-
pass a group of devastating conditions with high disease
burden presenting with substantial neurological dysfunc-
tion in previously healthy children [1–4]. IBrainDs result
from immune system activation against structures within
the central nervous system (CNS), including both the
brain and spinal cord, resulting in inflammation. Types of
IBrainD affecting children include small vessel childhood
primary angiitis of the CNS (SV-cPACNS), anti-N
-methyl-D-aspartate (NMDA) receptor encephalitis, mul-
tiple sclerosis (MS), and Rasmussen’s encephalitis. These
conditions often present acutely with one or more neuro-
logical symptoms, including cognitive and behavioural
dysfunction, seizure, hallucination and hemiparesis [1, 4–
7]. Systematic use of immunosuppressive therapy has
improved survival and reduced long-term neurological
deficits in childhood IBrainD, though significant burden of
illness still exists [5].
Health-related quality of life (HRQoL) is a concept
which considers the multidimensional contributions of
physical, emotional and social functioning when defining
wellbeing [8]. In pediatric populations especially, HRQoL
has become an important central outcome, requiring sep-
arate evaluation from traditional medical definitions of
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outcome such as mortality [8–10]. It is increasingly used
in both drug trials, and the clinical setting, to guide treat-
ment and rehabilitation decisions [8, 9]. The Pediatric
Quality of Life Inventory Version 4.0 Generic Core Scales
(PedsQL) is a validated questionnaire that assesses
pediatric HRQoL under four subdomains of functioning:
physical, emotional, social and school [9]. Thus, poor
PedsQL scores can reflect outcomes such as depression,
fatigue, poor school participation, and social strains, which
are difficult to quantify using other outcome scales but are
critical considerations for assessing the long-term burden
of IBrainD.
HRQoL in children with IBrainD has not yet been sys-
tematically evaluated. Although there is a perceived high
disease burden for children with IBrainD and their fam-
ilies, there is limited existing literature. The impact of
IBrainD on HRQoL, the clinical phenotypes associated
with poor HRQoL, the subdomains of functioning most
affected in IBrainD, and the relationship between early
and late measures of HRQoL are not currently known.
Therefore, the aims of the study were to [1] describe the
characteristics of patients with IBrainD, including clinical
phenotype and HRQoL, [2] compare both the burden of
IBrainD on the different subdomains within HRQoL, and
patient perspectives of HRQoL against parent/proxy per-
spectives in children with IBrainD and [3] identify trajec-
tories and risk factors for impaired HRQoL.
Patients and methods
Patients
This BrainWorks study was a multicenter, observational co-
hort study of children diagnosed with IBrainD between Au-
gust 2001 and August 2016. BrainWorks is an international
multicenter collaborative study aimed at increasing recogni-
tion, promoting rapid diagnostic evaluation and optimizing
treatment for pediatric IBrainD. For new patients enrolled
in BrainWorks, measurement of outcomes occurred at
pre-specified intervals, including diagnosis. Patients from
the BrainWorks study were included if they met diagnostic
criteria for an IBrainD as defined by the treating physician
at 18 years of age or younger, and had completed at least
one HRQoL Questionnaire.
Demographic and clinical features
Age at diagnosis, gender, and time to diagnosis were evalu-
ated. Diagnosis was categorized into small vessel childhood
primary angiitis of the CNS (SV-cPACNS), angiography
-positive non-progressive childhood primary angiitis of the
CNS (APNP-cPACNS), angiography-positive progressive
childhood primary angiitis of the CNS (APP-cPACNS),
antibody-mediated IBrainD, demyelinating IBrainD, granu-
lomatous IBrainD, Moyamoya phenotype, Secondary CNS
vasculitis, T-cell mediated IBrainD, and unclassified
IBrainD. Anti-NMDA receptor encephalitis, Hashimoto’s
encephalopathy, anti-glutamic acid decarboxylase antibody
encephalitis, mycoplasma-associated encephalitis and
neuromyelitis optica were categorized under antibody-me-
diated IBrainD.
Disease activity, damage and neurological functioning
Neurological clinical features at time-of-diagnosis col-
lected to the BrainWorks database included presence of
seizures (focal, generalized, or status epilepticus), hemipar-
esis and cognitive dysfunction. Cognitive dysfunction
included memory loss and behavioural abnormality.
Estimated disease activity and estimated damage were
measured as separate continuous variables using the
physician global assessment (PGA). Disease activity is
determined based on the presence of symptoms and
positive markers of disease activity, whereas estimated
damage is an estimate of permanent structural damage
and functional impairment. Both scores were reported
by physicians on a visual analog scale out of 10 cm,
where 0 cm represented no disease activity/estimated
damage and 10 cm represented high disease activity/esti-
mated damage.
Neurological functioning was characterized using the
pediatric stroke outcome measure (PSOM), which
assesses neurological and functional deficit across 5 sub-
scales: right sensorimotor, left sensorimotor, language
production, language comprehension and cognitive/be-
havioural deficit [11]. Overall neurological deficit in the
PSOM is scaled out of 10, with each subscale measured
out of 2. Higher values represent greater deficit. PSOM
score at 12 months was assessed as a discrete variable,
with any subscale score greater than 0.5 indicating the
presence of neurological dysfunction.
Health-related quality of life (HRQoL)
HRQoL was captured using the PedsQL, a validated tool
built of two 23-question surveys; one self-report for
pediatric patient completion, and one proxy-report for
completion by the patient’s parent or caregiver [12]. Both
PedsQL questionnaires were routinely completed at
time-of-diagnosis and at each follow-up clinical visit, clin-
ical situation permitting. Total PedsQL score was calcu-
lated for each report by taking the sum-total average of
item scores across the four subdomains [9]. PedsQL
scores were reported on a 0–100 scale, with higher scores
representing superior HRQoL.
The four subdomains of PedsQL are physical (8 items),
emotional (5 items), social (5 items) and school (5 items)
functioning. A score can be reported for each subdo-
main by taking a sum-total average of the individual
item scores within the subdomain. Alternatively, many
sources often report only two subdomain scores: phys-
ical functioning and psychosocial functioning, where the
psychosocial subdomain is a sum-total average of the
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item scores from the emotional, social and school func-
tioning sections of the questionnaire. All subdomain
PedsQL scores are also reported on a 0–100 scale, with
higher scores representing superior HRQoL.
Poor HRQoL was defined as a child’s self-reported
PedsQL score of ≤70, or a parent-proxy reported PedsQL
score ≤ 65. Various studies have established PedsQL
cut-off scores to differentiate good quality of life from not-
able impairment in quality of life, with the most frequent
cut-off scores reported to be in the range of 70–79 [9, 13–
15]. The cut-off scores for this study were chosen based
on a study by Kim et al., which concluded that a PedsQL
cut-off score of 70 separated patients with low symptoms
and high quality of life from those with moderate-to-se-
vere symptoms, and a study by Varni et al., which used
PedsQL child self-reported total scores of 69.1 and a
PedsQL parent proxy-reported total scores of 65.4 as
“meaningful cut-off point(s) for impaired HRQoL”, at one
standard deviation below the mean PedsQL score for
healthy children [9, 14].
Outcomes
The primary outcome assessed was the pediatric
HRQoL, defined by PedsQL total score. Secondary out-
comes were the HRQoL subdomains of physical, emo-
tional, social and school functioning.
Statistical analysis
Descriptive statistics for demographic and clinical vari-
ables are reported as means and standard deviation or
medians with interquartile range for continuous variables
and frequencies/proportions for categorical variables. Uni-
variable linear regression models with a maximum likeli-
hood algorithm for parameter estimation were used to
test the association between PedsQL scale and summary
scores with age at diagnosis, time to diagnosis, and esti-
mated damage at diagnosis as well as the association
between gender and the presence of hemiparesis, cogni-
tive/behavioural dysfunction, or seizures at diagnosis and
PedsQL scores at diagnosis. Regression models were ad-
justed for repeated measures with an autoregressive
covariance structure in order to establish whether these
relationships changed statistically significantly with time
(log transformed). Parameter estimate and its standard
error are reported, where parameter estimate represents
the change ratio for each increase of 1 unit in the inde-
pendent variable (unless otherwise indicated). Parameter
estimates were used to estimate the difference between
PedsQL scores of patients with different presentations at
time of diagnosis to account for the longitudinal analysis
and the variable PedsQL questionnaire completion. All
statistical test results were considered significant at the P
< .05 level. SAS 9.4 for Windows (SAS Institute Inc., Cary,
NC, USA) was used for all analyses.
Results
Patients
A total of 145 patients from 13 international sites were
included in the study; 80 (55%) female and 65 (45%)
male; median age at diagnosis 10.3 years (range = 0.4–
18.2 years); median time to diagnosis 1.2 months (range
= 0–120months); median follow-up of 24 months (range
= 0–160months) in the proxy-reports, and 28months
(range = 0–160 months) in the self-reports. The most
common diagnoses were SV-cPACNS (48 children,
33%), antibody-mediated IBrainD (28 children, 18%),
and APNP-cPACNS (22 children, 15%). One patient died.
Patient demographic data are summarized in Table 1.
Clinical presentation
The most frequently reported symptoms at diagnosis
were; cognitive/behavioural dysfunction 91 (63%)
patients, seizures 65 (45%), stroke 64 patients (44%). The
median disease activity score at diagnosis was high at 8.0
(range = 0–10), captured in 116 patients (80%). Neuro-
logic function 1 year after diagnosis was measured in
106 patients; 43 (41%) poor outcome and 63 good out-
come (59%). Clinical phenotypes and outcomes of the
patient population are summarized in Table 2.
Health related quality of life
A total of 145 patients completed at least one PedsQL
questionnaire; at time of diagnosis, 34 child self reports
and 39 parent proxy reports were completed. At 1 year
Table 1 Patient demographics for 145 pediatric patients with
inflammatory brain disease
Female. Number (%) 80 (55%)
Age at diagnosis, years. Median (range) 10.3 (0.4–18.2)
Diagnosis
Small vessel cPACNS 48 (33%)
Angiography positive, non-progressive cPACNS 22 (15%)
Angiography positive, progressive cPACNS 8 (6%)
Antibody-mediated IBrainD 26 (18%)
Anti-NMDA receptor encephalitis 13 (9%)
Other antibody-mediated 13 (9%)
Secondary IBrainD 12 (8%)
Secondary CNS Vasculitis 10 (7%)
Demyelinating 4 (3%)
Granulomatosis IBrainD 2 (1%)
Moyamoya-like 1 (1%)
T-cell mediated IBrainD 2 (1%)
IBrainD NYD 10 (7%)
Time to diagnosis, months. Median (range) 1.2 (0–150)
Legend: Acronyms: CNS Central nervous system, cPACNS Childhood primary
angiitis of the central nervous system, IBrainD Inflammatory brain disease, NYD
Not yet determined
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after diagnosis 47 child self reports and 48 parent proxy
reports were completed. A total of 98 patients com-
pleted a PedsQL questionnaire at more than one time
point. Reasons for inability to complete the PedsQL were
language limitations, poor medical status, lack of request
by contributing physicians, or death.
The mean PedsQL scores at diagnosis were below
the threshold reflecting poor HRQoL for both the
child’s self-reported (mean 68.4 (range = 20.7–98.9))
and the parent proxy-reported (mean 63.4 (range =
13.0–98.9)). A total of 73 PedsQL questionnaires were
completed at diagnosis: 34 child’s self-report and 39
parent’s proxy-report. Poor HRQoL at diagnosis was
reported in 53% (18/34) of children, defined by
PedsQL total scores less than or equal to 70, and
48% (19/39) of parents, defined by PedsQL scores of
less than or equal to 65.
Mean PedsQL scores trended upward 1 year after diag-
nosis. A total of 95 PedsQL questionnaires were com-
pleted at 1 year after diagnosis; 47 child’s self-reports and
48 parent’s proxy-reports. The mean child’s self-reported
PedsQL score 1 year after diagnosis was 72.5 (range = 6.3–
98.9), while the mean parent proxy-reported PedsQL
score was 66.7 (range = 14.1–95.65). A total of 34% (16/
47) of children and 35% (17/48) of parents reported poor
HRQoL 1 year after diagnosis.
HRQoL at diagnosis and at 1 year after diagnosis are
described in Table 2.
HRQoL subdomain functioning from parent and child
perspectives at time-of-diagnosis
The mean child self-reported PedsQL subdomain score at
diagnosis were; 67.9 (range = 9.4–100.0) physical function-
ing, 70.9 (range = 35.0–100.0) emotional functioning, 56.3
(range = 0.0–100.0 school functioning, and 78.7 (range =
0.0–100.0) social functioning. The mean parent proxy-re-
ported PedsQL subdomain scores at diagnosis were; 61.4
(range = 0.0–100.0) physical functioning, 63.8 (range =
20.0–100.0) emotional functioning, 57.4 (range = 0.0–
100.0) school functioning, and 74.0 (range = 0.0, 100.0)
social functioning (see Fig. 1).
Predictors of impaired HRQoL
The impact of patient characteristics and presenting
clinical features on trajectories of HRQoL is summarized
in Table 3, with increased risk of impaired HRQoL
reflected by more negative parameter estimates.
Children with seizures at diagnosis had an increased
risk of poor HRQoL, with dramatic impairments in
both physical and psychosocial functioning subdo-
mains. Child’s self-reported total PedsQL score at
time-of-diagnosis was 15.6 points lower (p < 0.01) in
children who had seizures at diagnosis, while the par-
ent’s proxy-reported total PedsQL score at diagnosis
was 11.5 points lower (p < 0.01), when compared to
patients without seizures. PedsQL physical subdomain
score at time-of-diagnosis was lower by 13.4 points
(p < 0.01) in the child self-report in patients with sei-
zures at diagnosis, and 9.9 points lower at time
-of-diagnosis in the parent proxy-report, though not
statistically significant (p = 0.10). Compared to patients
without seizures at diagnosis, the child self-reported
psychosocial subdomain PedsQL score at time
-of-diagnosis was lower by 16.2 points (p < 0.01) in
patients with seizures at diagnosis, and the parent
proxy-reported psychosocial subdomain PedsQL score
at diagnosis was lower by 12.4 points (p < 0.01). All
reported values are parameter estimates at time
-of-diagnosis.
Table 2 Clinical phenotypes and outcomes for 145 pediatric
patients with inflammatory brain disease
Clinical phenotypes at diagnosis
Presenting symptoms
Cognitive Dysfunction 91 (63%)
Seizures 65 (45%)
Hemiparesis 64 (44%)
Disease activity
Number of patients with disease
activity measurements
116 (80%)
Median (Range) 8.0 (0–10)
Estimated damage
Number of patients with estimated
damage measurements
98 (68%)
Median (Range) 1.0 (0–8)
Poor health-related quality of life
Child’s self-reported 53% (18/34)
Parent’s proxy-reported 49% (19/39)
Outcomes
Survival 144/145 (99%)
Neurologic function at 1 year
Number of patients with neurologic
function measurements
106 (73%)
Good 63/106 (59%)
Poor 43/106 (41%)
Poor health-related quality of life at 1 year
Child’s self-reported 34% (16/47)
Parent’s proxy-reported 35% (17/48)
Legend: Disease activity and estimated damage were measured using the
physician global assessment (PGA). The PGA is measured on a continuous
scale from 0 to 10, with 0 representing no disease activity/damage, and 10
representing severe disease activity/damage. Neurologic function was
measured using the pediatric stroke outcome measure (PSOM), with the
presence of significant dysfunction in any of the 5 subdomains (right
sensorimotor, left sensorimotor, language production, language
comprehension and cognitive/behavioural deficit) indicating poor
neurologic function
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Presenting with cognitive (and/or behavioural) dysfunc-
tion was a significant risk factor for impaired functioning
across all subdomains. When compared to patients whith-
out cognitive dysfunction, the child self-reported total
PedsQL in patients presenting with cognitive dysfunction
was 15.0 points lower (p < 0.01) at time-of-diagnosis, the
PedsQL physical subdomain score was 14.4 points lower
(p < 0.01), and PedsQL psychosocial score was 15.3 points
lower (p < 0.01). In the parent proxy-reports, cognitive
dysfunction was associated with a decrease in the total
PedsQL at time-of-diagnosis of 15.2 points (p < 0.01), and
decrease in the psychosocial PedsQL at time-of-diagnosis
of 17.7 points (p < 0.01). Cognitive dysfunction trended
with a physical subdomain score at time-of-diagnosis 11.4
points lower than for those without cognitive dysfunction
(p = 0.07). All reported values are parameter estimates at
time-of-diagnosis, and are presented in Table 3.
Hemiparesis at diagnosis was not found to be a risk
factor for impaired HRQoL.Male and female pediatric
IBrainD patients did not have statistically different per-
ceptions of physical or psychosocial functioning.
Trajectories of HRQoL
Overall HRQoL, physical functioning, and psychosocial
functioning were found to improve with time for all
pediatric IBrainD patients, reflected by improving PedsQL
scores with increasing log-transformed time from diagno-
sis. The relative improvement in HRQoL varied according
to presenting features.
From the child’s perspective, improvement in HRQoL
over time was seen in pediatric patients presenting with
seizures or with cognitive/behavioural dysfunction relative
to patients without these presenting features. This
improvement was not observed from the parent’s view-
point. Regression models adjusted for repeated measures
showed that the overall HRQoL impairment for pediatric
IBrainD patients presenting with seizures decreased with
time (β = 2.7, SE =1.4, p = 0.05). From a separate model
completed using the same methodology, patients with
cognitive/behavioural dysfunction at diagnosis were found
to self-report decreased overall HRQoL impairment (β =
3.5, SE =1.5, p = 0.02), as well as decreased impairment in
psychosocial functioning over time (β = 3.6, SE =3.9, p =
0.02), when compared to patients without cognitive/be-
havioural dysfunction at diagnosis. Parent-perceived
impairment in psychosocial functioning was found to de-
crease with log-transformed time for patients with cogni-
tive dysfunction at diagnosis (β = 8.0, SE =3.9, p = 0.04).
By contrast, according to children’s self-reports, there
was no improvement in physical functioning in patients
presenting with either seizures or cognitive dysfunction
compared to IBrainD patients who presented without
these clinical features. Impairments in psychosocial func-
tioning were not seen to decrease with time in patients
presenting with seizures, relative to IBrainD patients with-
out these clinical features. Parents did not perceive a de-
crease in impairment in overall HRQoL with increasing
log-transformed time, for patients with seizures or cogni-
tive dysfunction at diagnosis, compared to reports from
parents of IBrainD patients without these clinical features.
Parents also did not perceive decreased impairment in
psychosocial functioning with increased log-transformed
Fig. 1 Health-related quality of life in children newly diagnosed with inflammatory brain disease, from the child’s perspective and the parent’s
perspective. Legend: n = 34 for child’s self-reported PedsQL scores, and n = 39 for parent’s proxy-reported PedsQL scores. Reported values are
mean baseline subdomain and overall PedsQL scores, out of 100, with larger scores representing improved quality of life
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time for patients with seizures at diagnosis compared to
patients without seizures at diagnosis.
Continuous variables with associations with HRQoL
Improvement of HRQoL, reflected by improved PedsQL
scores, was associated with older age at diagnosis, increased
time between presentation and diagnosis, lower estimated
damage at diagnosis, and higher estimated disease activity
at diagnosis. Only the association between improvement of
HRQoL and higher initial disease activity was statistically
significant (β = 8.0, SE =3.9, p = 0.04). These trends were
not found to significantly change with time.
Discussion
This is the first study to systematically evaluate the
impact of pediatric IBrainD on both overall HRQoL and
its various subdomains. HRQoL is a multi-dimensional
measurement used to estimate burden of disease. In the
context of pediatric IBrainD, HRQoL will be critical in
ensuring effective dialogue with affected children and
families, and shaping future rehabilitation efforts. In
IBrainD, the various subdomains of HRQoL are signifi-
cantly impacted, with the greatest burden of disease in
children presenting with cognitive/behavioural dysfunc-
tion or seizures.
HRQoL in pediatric patients with IBrainD is signifi-
cantly impaired, with mean PedsQL scores at diagnosis
consistently dramatically lower than mean PedsQL
scores in healthy children, as reported by Varni et al.,
reflecting significant burden of disease [9]. Based on
greater than 5000 child self-reports, Varni et al. deter-
mined the mean total PedsQL score in healthy children
to be 83.9 (SD = 12.5) [9]. This is almost 25% higher
than the mean PedsQL score for children with IBrainD.
School functioning was found to be the most affected
PedsQL subdomain at baseline; Varni et al.’s healthy
pediatric population had a mean PedsQL score almost
1.5 times greater than children newly diagnosed with
IBrainD [9]. Social functioning was found to be the least
affected of all the subdomains, with healthy children
scoring 8% higher than pediatric IBrainD patients [9].
The mean physical and emotional subdomain PedsQL
Table 3 Impact of baseline patient characteristics and presenting clinical features on trajectories of health-related quality of life
(HRQoL) over time
Child self-reported HRQoL
Parameter estimate β (SEb)
P value Parent proxy-reported HRQoL
Parameter estimate β (SEb)
P value
Predictors for impaired overall
HRQoL trajectories over time
Female Gender (vs. Male) −7.6 (4.6) 0.10 −3.8 (4.4) 0.39
Seizures −15.6 (4.6)a < 0.01 −11.5 (4.4) < 0.01
Cognitive Dysfunction − 15.0 (4.8)a < 0.01 −15.2 (4.6) < 0.01
Hemiparesis −2.9 (4.6) 0.53 −2.5 (4.4) 0.58
Predictors for impaired physical
functioning trajectories over time
Female Gender (vs. Male) −8.9 (5.6) 0.12 −7.8 (5.9) 0.19
Seizures −13.4 (5.7) 0.02 −9.9 (6.0) 0.10
Cognitive Dysfunction −14.4 (5.9) 0.02 −11.4 (6.2) 0.07
Hemiparesis −7.3 (5.7) 0.20 −1.7 (5.9) 0.77
Predictors for impaired psychosocial
functioning trajectories over time
Female Gender (vs. Male) −7.1 (4.7) 0.13 −1.6 (4.3) 0.71
Seizures −16.2 (4.7) < 0.01 −12.4 (4.3) < 0.01
Cognitive Dysfunction −15.3 (4.9)a < 0.01 −17.7 (4.4)a < 0.01
Hemiparesis −0.1 (4.7) 0.98 −0.1 (4.7) 0.44
Legend: Health-related quality of life (HRQoL) was measured using PedsQL 4.0 Generic Core Scales. Child-reported HRQoL was measured using the child self-
reporting PedsQL questionnaire. PedsQL scores are between 0 and 100, with higher values representing better HRQoL. Negative changes in HRQoL associated
with a clinical phenotype therefore represent risk factors for impaired HRQoL. 464 child self-reported PedsQL questionnaires were completed and used in this
analysis. Each parameter estimate was derived from a separate, univariable linear regression model, adjusted for time, evaluating the impact of the predictor
alongside time on HRQoL. Regression models were adjusted for repeated measures with an autoregressive covariance structure to establish whether these
relationships changed statistically significantly with time
n = 145 patients
aasterisk indicates that the HRQoL impairment associated with the presence of the clinical variable at diagnosis is time-dependent, with the gap in HRQoL
between patients with the clinical variable at diagnosis and patients who do not have the clinical variable at diagnosis decreasing with increasing time. This was
only assessed in clinical parameters with statistically significant parameter estimates
bSE Standard error
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scores for healthy children as reported by Varni et al.
were 24 and 12% higher, respectively, than those calcu-
lated for pediatric patients newly diagnosed with IBrainD
[9]. This follows a similar trend to pediatric patients
with MS; in a study by MacAllister, 46% of pediatric
patients with MS self-reported physical impairment, 42%
academic impairment, 28% emotional impairment, and
only 14% social impairment at baseline [16]. A study by
Russell et al. following adolescents with sports-related
concussions found the greatest impairments at clinical
presentation to be in the physical and cognitive subdo-
mains [17]. School functioning for patients with IBrainD
is especially affected at time of diagnosis, potentially due
to extensive school absences owing to hospitalization.
Consequently, attention should be given to determine if
poor school functioning in children with IBrainD
recovers with time or if additional cognitive rehabilita-
tion services are required.
Children presenting with seizures or cognitive/behav-
ioural dysfunction have an especially high risk of
long-term impairment of HRQoL, with reduced mean
PedsQL scores across all subdomains of HRQoL. These
findings were consistent with findings in a study of
children following acquired brain injury, where
post-injury cognition/learning impairment was associ-
ated with worse overall HRQoL, particularly in the
psychosocial domain, and post-injury behavioural im-
pairment was moderately associated with reduced
psychosocial functioning [18]. It may be postulated that
seizures and cognitive/behavioural dysfunction fit
within a phenotypic cluster associated with certain con-
ditions previously identified to have poorer prognoses;
for example, concentration difficulties, cognitive dys-
function, and mood/personality changes were found to
be more common in the APP-cPACNS population,
whereas hemiparesis was found to occur more fre-
quently in the APNP-cPACNS cohort and seizures were
common in SV-cPACNS [1, 19]. Alternatively, the prog-
nosis of pediatric IBrainD patients with hemiparesis
may be more favorable as a result of high availability
and routine utilization of targeted physical rehabilita-
tion efforts for children with physical impairment. In
comparison, rehabilitation efforts and social services
targeting children with seizures or pathological cogni-
tive and/or behavioural dysfunction is typically limited
or absent. Though mean HRQoL tended to increase for
all patients, as consistent with the ‘response shift’
process [20], the impairments in functioning associated
with seizures were found to persist through time, and
the diminished quality of life associated with behav-
ioural/cognitive dysfunction was found to recover only
very slowly. More rigorous and targeted attention and
intervention should be initiated at diagnosis for this
group of patients.
There are a number of limitations to this study. One
limitation concerns generalizability to children with
IBrainD presenting with severe disability, as acutely hospi-
talized children with significant impairment were often
unable to complete the PedsQL questionnaires. As a
result, the true impact was likely underestimated in this
study. Specifically, the self-reported pediatric HRQoL for
children with cognitive dysfunction at diagnosis was likely
significantly poorer than reported, as this population likely
encountered significant barriers understanding and com-
pleting the PedsQL questionnaires. In addition, while the
results are applicable to IBrainD as a whole, they may not
be generalizable to all distinct disease subtypes, explaining
the variability of patient presentations. For example, while
some IBrainDs have abrupt and severe symptom onset,
others progress more insidiously, often resulting in a pro-
longed time to diagnosis. Separation of these disease sub-
types may be considered for future studies. Finally, the
BrainWorks study was a largely unfunded, international,
multi-center study, and accordingly, adherence to study
guidelines was variable, resulting in missing and incom-
plete data. However, as this study is the first to evaluate
HRQoL in pediatric IBrainD patients using validated study
instruments, it is the only information to date pertaining
to the impact of any of the pediatric IBrainDs on percep-
tions of functioning and disability. Analysis of this data
provides valuable initial documentation of the burden of
IBrainD.
Conclusion
This study is the first to evaluate the burden of
pediatric IBrainD on the HRQoL. While differences of
opinion exist regarding whether the greatest value
from the PedsQL tool is ascertained through the
objective components, such as observation of activity
and interaction by parents via the parent-proxy
report, or via the subjective component that allows
the child to self-report their own experience of im-
pairment, it is agreed upon that the PedsQL can pro-
vide valuable insight into the patient experience of
illness [10]. IBrainD was found to result in significant
HRQoL impairment, with the greatest disabilities in
the school functioning and physical functioning sub-
domains at diagnosis. Children presenting with sei-
zures and cognitive dysfunction were found to have a
higher risk of impairment, both at diagnosis and in
the future, mandating improvements in rehabilitation
and social service strategies targeting these patients.
While rehabilitation programs targeting physical defi-
cits are currently robust, there is a clear unmet
demand for rehabilitation for children with pathologic
cognitive or behavioral dysfunction, targeting psycho-
social recovery. Future work should strive to improve
the prognosis for children with IBrainD, especially
Liu et al. Pediatric Rheumatology           (2018) 16:73 Page 7 of 8
those presenting with risk factors for increased bur-
den of disease. Identification of patients with in-
creased risk of poor HRQoL should be followed by
the provision of targeted rehabilitation, which aims to
improve functioning in the subdomains predicted to
have weak recovery.
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